Clinical Trial Update: A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluated escalating doses of PRO131921 in patients with indolent non-Hodgkin lymphoma to assess safety and preliminary activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• PRO131921

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: TERMINATED